vs
Community West Bancshares（CWBC）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是Community West Bancshares的2.0倍（$75.5M vs $38.3M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 11.6%），Community West Bancshares自由现金流更多（$43.6M vs $14.4M），过去两年Community West Bancshares的营收复合增速更高（36.0% vs 31.3%）
Community West Bancshares是一家总部位于美国加利福尼亚州的注册银行控股公司，依据银行控股公司相关法案全资持有Community West Bank，开展银行相关控股经营业务。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
CWBC vs PBYI — 直观对比
营收规模更大
PBYI
是对方的2.0倍
$38.3M
营收增速更快
PBYI
高出16.2%
11.6%
自由现金流更多
CWBC
多$29.2M
$14.4M
两年增速更快
CWBC
近两年复合增速
31.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $38.3M | $75.5M |
| 净利润 | — | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | 40.0% | 22.7% |
| 净利率 | — | — |
| 营收同比 | 11.6% | 27.7% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.58 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CWBCPBYI
| Q4 25 | $38.3M | $75.5M | ||
| Q3 25 | $37.9M | $54.5M | ||
| Q2 25 | $35.7M | $52.4M | ||
| Q1 25 | $34.8M | $46.0M | ||
| Q4 24 | $34.3M | $59.1M | ||
| Q3 24 | $31.3M | $80.5M | ||
| Q2 24 | $30.5M | $47.1M | ||
| Q1 24 | $20.7M | $43.8M |
净利润CWBCPBYI
| Q4 25 | — | — | ||
| Q3 25 | $10.9M | $8.8M | ||
| Q2 25 | $7.8M | $5.9M | ||
| Q1 25 | $8.3M | $3.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $3.4M | $20.3M | ||
| Q2 24 | $-6.3M | $-4.5M | ||
| Q1 24 | $3.7M | $-4.8M |
毛利率CWBCPBYI
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
营业利润率CWBCPBYI
| Q4 25 | 40.0% | 22.7% | ||
| Q3 25 | 39.8% | 17.6% | ||
| Q2 25 | 30.2% | 12.7% | ||
| Q1 25 | 32.7% | 8.7% | ||
| Q4 24 | 31.0% | 22.6% | ||
| Q3 24 | 13.3% | 27.4% | ||
| Q2 24 | -25.9% | -4.6% | ||
| Q1 24 | 23.2% | -5.3% |
净利率CWBCPBYI
| Q4 25 | — | — | ||
| Q3 25 | 28.7% | 16.2% | ||
| Q2 25 | 22.0% | 11.2% | ||
| Q1 25 | 23.8% | 6.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.8% | 25.2% | ||
| Q2 24 | -20.7% | -9.6% | ||
| Q1 24 | 17.8% | -11.0% |
每股收益（稀释后）CWBCPBYI
| Q4 25 | $0.58 | $0.26 | ||
| Q3 25 | $0.57 | $0.17 | ||
| Q2 25 | $0.41 | $0.12 | ||
| Q1 25 | $0.44 | $0.06 | ||
| Q4 24 | $0.29 | $0.40 | ||
| Q3 24 | $0.18 | $0.41 | ||
| Q2 24 | $-0.33 | $-0.09 | ||
| Q1 24 | $0.31 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $119.0M | $97.5M |
| 总债务越低越好 | $69.5M | $22.7M |
| 股东权益账面价值 | $409.6M | $130.3M |
| 总资产 | $3.7B | $216.3M |
| 负债/权益比越低杠杆越低 | 0.17× | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资CWBCPBYI
| Q4 25 | $119.0M | $97.5M | ||
| Q3 25 | $121.6M | $94.4M | ||
| Q2 25 | $134.4M | $96.0M | ||
| Q1 25 | $148.4M | $93.2M | ||
| Q4 24 | $120.4M | $101.0M | ||
| Q3 24 | $149.0M | $96.7M | ||
| Q2 24 | $109.7M | $96.8M | ||
| Q1 24 | $61.0M | $107.2M |
总债务CWBCPBYI
| Q4 25 | $69.5M | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | $69.9M | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益CWBCPBYI
| Q4 25 | $409.6M | $130.3M | ||
| Q3 25 | $397.6M | $115.3M | ||
| Q2 25 | $380.0M | $104.7M | ||
| Q1 25 | $372.2M | $97.1M | ||
| Q4 24 | $362.7M | $92.1M | ||
| Q3 24 | $363.5M | $71.1M | ||
| Q2 24 | $350.2M | $48.5M | ||
| Q1 24 | $211.7M | $51.0M |
总资产CWBCPBYI
| Q4 25 | $3.7B | $216.3M | ||
| Q3 25 | $3.6B | $202.9M | ||
| Q2 25 | $3.6B | $194.9M | ||
| Q1 25 | $3.6B | $196.2M | ||
| Q4 24 | $3.5B | $213.3M | ||
| Q3 24 | $3.5B | $220.7M | ||
| Q2 24 | $3.5B | $205.0M | ||
| Q1 24 | $2.4B | $214.1M |
负债/权益比CWBCPBYI
| Q4 25 | 0.17× | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | 0.19× | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $46.1M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $43.6M | $14.4M |
| 自由现金流率自由现金流/营收 | 113.9% | 19.1% |
| 资本支出强度资本支出/营收 | 6.6% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $77.7M | $41.7M |
8季度趋势，按日历期对齐
经营现金流CWBCPBYI
| Q4 25 | $46.1M | $14.4M | ||
| Q3 25 | $13.2M | $9.7M | ||
| Q2 25 | $11.5M | $14.1M | ||
| Q1 25 | $11.1M | $3.6M | ||
| Q4 24 | $22.2M | $15.6M | ||
| Q3 24 | $7.8M | $11.0M | ||
| Q2 24 | $5.2M | $1.0M | ||
| Q1 24 | $4.0M | $11.2M |
自由现金流CWBCPBYI
| Q4 25 | $43.6M | $14.4M | ||
| Q3 25 | $12.8M | $9.7M | ||
| Q2 25 | $10.6M | $14.1M | ||
| Q1 25 | $10.8M | $3.6M | ||
| Q4 24 | $17.2M | $15.6M | ||
| Q3 24 | $5.2M | $11.0M | ||
| Q2 24 | $4.8M | $1.0M | ||
| Q1 24 | $3.6M | — |
自由现金流率CWBCPBYI
| Q4 25 | 113.9% | 19.1% | ||
| Q3 25 | 33.7% | 17.7% | ||
| Q2 25 | 29.6% | 26.8% | ||
| Q1 25 | 30.9% | 7.7% | ||
| Q4 24 | 50.0% | 26.4% | ||
| Q3 24 | 16.7% | 13.7% | ||
| Q2 24 | 15.7% | 2.1% | ||
| Q1 24 | 17.3% | — |
资本支出强度CWBCPBYI
| Q4 25 | 6.6% | 0.0% | ||
| Q3 25 | 1.1% | 0.0% | ||
| Q2 25 | 2.7% | 0.0% | ||
| Q1 25 | 0.9% | 0.1% | ||
| Q4 24 | 14.7% | 0.0% | ||
| Q3 24 | 8.1% | 0.0% | ||
| Q2 24 | 1.4% | 0.0% | ||
| Q1 24 | 2.1% | 0.0% |
现金转化率CWBCPBYI
| Q4 25 | — | — | ||
| Q3 25 | 1.21× | 1.10× | ||
| Q2 25 | 1.47× | 2.41× | ||
| Q1 25 | 1.33× | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.29× | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.09× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
